FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
    12.
    发明公开
    FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF 审中-公开
    缩合的嘧啶,中级和工艺制备该组合物及其用途

    公开(公告)号:EP3053926A4

    公开(公告)日:2017-05-03

    申请号:EP14847916

    申请日:2014-09-17

    发明人: XU ZUSHENG

    摘要: Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applictions of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

    摘要翻译: 本发明公开了稠合的嘧啶化合物,中间体,用于其的制备方法,和一种组合物并涉及其应用。 本发明提供了式I中,药学上可接受的盐,水合物,溶剂化物表示的稠合嘧啶化合物,以及旋光异构体或该化合物的前药。 本发明进一步提供了式I中,药学上可接受的盐,水合物,溶剂化物,以及光学异构体或该化合物的在制备药物的前体药物用于治疗和/或预防激酶相关所示的稠合嘧啶化合物的applictions 疾病。 本发明的稠合嘧啶化合物I是一种有效的PI3激酶抑制剂,并且可用于预防和/或固化的细胞增殖性疾病的药物制备:如癌症,感染,炎症和自身免疫性疾病。

    FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF
    13.
    发明公开
    FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF 审中-公开
    稠合杂环化合物,用于生产该药物组合物及其用途

    公开(公告)号:EP3059238A1

    公开(公告)日:2016-08-24

    申请号:EP14853907.5

    申请日:2014-09-19

    摘要: Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3K δ , and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.